Abstract
ObjectivesAn effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India.DesignDouble-blind, randomized, placebo controlled trialSettingThe trial was conducted in the clinical trial ward of the Infectious Diseases Hospital in Kolkata, IndiaParticipantsThe participants were 101 healthy adults (males and non-pregnant females) aged 18–40 years and 100 healthy children (males and non-pregnant females) aged 1–17 years.InterventionsParticipants were randomized to receive either the bivalent killed whole cell oral cholera vaccine or placebo (killed oral Escherichia coli K12)Outcome MeasuresFor safety: proportion of subjects with adverse events during the duration of study participation. For immunogenicity: Proportion of subjects who had a ≥4-fold rise in serum vibriocidal antibody titers 14 days after the second dose of vaccine or placebo.ResultsAdverse reactions were observed with similar frequency among vaccine and placebo recipients in both age groups. Among adults 4% of vaccine and 8% of placebo recipients and among children 4% of vaccine and 2% of placebo recipients had at least one adverse event within 28 days of the first dose of the vaccine. Following immunization, 53% of adult and 80% of children vaccinees showed a ≥4 fold rise in serum V. cholerae O1 vibriocidal antibody titers. A less pronounced response to V. cholerae O139 vibriocidal antibody titers post-immunization was noted among vaccinees.ConclusionsWe found the vaccine to be safe and immunogenic in a cholera-endemic area in India.Trial RegistrationClinicalTrials.gov NCT00119197
Highlights
The World Health Organization (WHO) advocates the use of oral cholera vaccines in the control of cholera in addition to other control measures [1]
A less pronounced response to V. cholerae O139 vibriocidal antibody titers post-immunization was noted among vaccinees
Vietnam produces a two-dose, oral killed whole cell cholera vaccine that has been given through its public health system and is currently produced at about US$0.40 per dose
Summary
The World Health Organization (WHO) advocates the use of oral cholera vaccines in the control of cholera in addition to other control measures [1]. Vietnam produces a two-dose, oral killed whole cell cholera vaccine that has been given through its public health system and is currently produced at about US$0.40 per dose. This bivalent (Vibrio cholerae 01 and 0139) vaccine and its monovalent (O1) predecessor have been found to be safe and to confer significant protection against El Tor cholera in both children and adults [2,3,4]. No serious adverse events have been associated with this vaccine [5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.